Substandard control arms question the utility of some new cancer drugs
ADOBE
New cancer drugs should be tested against treatments that represent the current standard of care. A new analysis suggests that often doesn't happen.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario